Recent Advances in Active Hepatic Targeting Drug Delivery System

Author(s): Yang Wang, Hongliang Du, Guangxi Zhai

Journal Name: Current Drug Targets

Volume 15 , Issue 6 , 2014

Become EABM
Become Reviewer
Call for Editor


Hepatic diseases are turning into one of the few diseases that cannot be effectively cured due to some reasons although various receptors existed in the liver. Currently, several passive targeting delivery systems have been used in the drug/gene delivery for the treatment of hepatic diseases. For example, Zinostatin stimalamer (trade name of Smancs®), a drug-polymer conjugate, was launched in Japan in 1994, which treats hepatocellular carcinoma. More improtantly, different measures would be taken in accord to the specified cell that was lesioned or dysfunctioned via interaction between homing ligands and target receptors so as to improve accumulation of drugs in the target cell and to reduce nonspecific toxicity towards other cells or organs. Therefore, it is urgent to design novel delivery systems that physically or chemically grafted homing devices in order to improve the targeting properties of drugs in specific cell sites. From that perspective, the present article highlights recent development of active hepatic targeting drug/gene delivery systems for the treatment of hepatic diseases that were mediated by some kinds of receptors including asialoglycoprotein receptors (ASGP-R), glycyrrhetinic acid receptor (GA-R), glycyrrhizin receptor (GL-R), hyaluronan receptor (HA-R) and so on.

Keywords: Active hepatic targeting, drug carriers, drug delivery, homing ligands.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 14 April, 2014
Page: [573 - 599]
Pages: 27
DOI: 10.2174/1389450115666140309232100
Price: $65

Article Metrics

PDF: 87